The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

Disclosed herein is a nanoparticle composition comprising nanoparticles formed from one of: a conjugate of dimeric epigallocatechin-3-O-gallate and hyaluronic acid; a conjugate of epigallocatechin-3-O-gallate and hyaluronic acid; or a epigallocate-chin-3-O-gallate-terminated hyaluronic acid conjugate; and an active agent or a pharmaceutically acceptable salt, solvate or prodrug 0thereof suitable to treat acute myeloid leukaemia, wherein the active agent is encapsulated in the nanoparticles.

Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.

The present invention relates to conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising drugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said conjugates and the use of said conjugates as medicaments.

A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.

A nanocomplex, 50 to 1000 nm in size, containing a lipid-like nanoparticle formed of a cationic lipid-based compound and a modified protein formed of a protein and an anionic polymer that includes a plurality of polar groups, the lipid-like nanoparticle and the modified protein being non-covalently bonded to each other. Also disclosed are a method of preparing the above-described nanocomplex and use thereof for treating a medical condition. Further disclosed is a pharmaceutical composition containing a nanocomplex.

The present invention comprises a process for preparing water-dispersible single-chain polymeric nanoparticles, which comprises cross-linking a polymer having a solubility equal to or higher than 100 mg per litre of water, and an amount of complementary reactive groups comprised from 5 to 60 molar % of the total amount of monomer units present in the polymer chain; with a crosslinking agent having crosslinkable groups; at a temperature comprised from 20 to 25° C. in the absence of a catalyst; to obtain water-dispersible conjugates and compositions containing the nanoparticle; and the use thereof.

A gene nanocomposite and a cellular internalization method of a gene using the same are provided. More specifically provided is a gene nanocomposite including: a photosensitizer-conjugated polymer; and one or more materials selected from a gene and a gene/cationic polymer composite, and a cellular internalization method of a gene using the same to improve gene delivery efficiency into a mammal-derived cell and gene expression.

A protein functionalized anti-inflammatory nanoparticle and a method of preparing the protein functionalized anti-inflammatory nanoparticle is disclosed. The protein functionalized anti-inflammatory nanoparticle includes a central core comprising a hyaluronic acid coated chitosan nanoparticle and surface adsorbed anti-inflammatory proteins forming an outer shell around the central core, wherein the surface adsorbed anti-inflammatory protein is AGP (alpha-1-acid glycoprotein). The method of preparation includes dispersing chitosan nanoparticles in acetic acid/acetate buffer to produce a dispersion, adding an equal amount of acetate buffer containing hyaluronic acid under vigorous stirring to form hyaluronic coated chitosan nanoparticle (HA-CS) and functionalizing the hyaluronic coated chitosan nanoparticle with surface adsorbing anti-inflammatory protein AGP, to form the protein functionalized anti-inflammatory nanoparticle.